Indivior Pharmaceuticals Inc (INDV) Earnings History
Profitable10 years of earnings data (2016–2025) · Positive TTM net income
Loading earnings history...
Indivior Pharmaceuticals Inc (INDV) Earnings Overview
As of June 28, 2026, Indivior Pharmaceuticals Inc (INDV) reported trailing twelve-month net income of $251M, reflecting +10833.3% year-over-year growth. The company earned $1.95 per diluted share over the past four quarters, with a net profit margin of 16.9%.
Looking at the long-term picture, INDV's historical earnings data spans multiple years. The company achieved its highest annual net income of $263M in fiscal 2018.
Indivior Pharmaceuticals Inc maintains industry-leading profitability with a gross margin of 80.1%, operating margin of 21.4%, and net margin of 16.9%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RBBN ($31M net income, 4.7% margin), AVPT ($47M net income, 8.4% margin), BHVN (-$648M net income), INDV has outperformed on profitability metrics. Compare INDV vs RBBN →
INDV Earnings vs Peers
Earnings metrics vs comparable public companies
INDV Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $210M | +10400.0% | $265M | $1.64 | 16.9% | 21.4% |
| 2024 | $2M | +101.6% | $32M | $0.01 | 0.2% | 2.7% |
| 2023 | -$129M | -193.2% | -$156M | $0.01 | -11.8% | -14.3% |
| 2022 | -$44M | -121.5% | -$81M | $-0.37 | -4.9% | -9.0% |
| 2021 | $205M | +238.5% | $213M | $1.31 | 25.9% | 26.9% |
| 2020 | -$148M | -210.4% | -$156M | $-1.08 | -22.9% | -24.1% |
| 2019 | $134M | -49.0% | $178M | $0.92 | 17.1% | 22.7% |
| 2018 | $263M | +331.1% | $317M | $1.75 | 27.4% | 33.0% |
| 2017 | $61M | +90.1% | $423M | $0.41 | 5.3% | 36.9% |
| 2016 | $32M | - | $338M | $0.22 | 3.3% | 34.9% |
Download Data
Export INDV earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INDV — Frequently Asked Questions
Quick answers to the most common questions about buying INDV stock.
What is INDV earnings per share (EPS)?
INDV trailing twelve-month (TTM) diluted EPS is $1.95, reflecting +10833.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Indivior Pharmaceuticals Inc's net income?
Indivior Pharmaceuticals Inc (INDV) trailing twelve-month net income is $251M as of 2025. Earnings grew +10833.3% year-over-year. Indivior Pharmaceuticals Inc has been profitable for 2 consecutive years.
Is INDV profitable?
Yes, INDV is profitable with a TTM net income of $251M and a net profit margin of +16.9%. Indivior Pharmaceuticals Inc has generated profits for 2 consecutive years.
What is INDV's earnings growth rate?
INDV compound annual EPS growth rates (CAGR): 1-Year: +10833.3%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are INDV's profit margins?
Indivior Pharmaceuticals Inc net profit margin is +16.9%, operating margin is +21.4%, and gross margin is +80.1%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.
Is INDV growing earnings?
Yes, INDV earnings are accelerating — EPS growth of +10833.3% exceeds the 5-year CAGR of N/A. TTM net income reached $251M. Earnings momentum is strengthening.
What was INDV's best earnings year?
Indivior Pharmaceuticals Inc's highest annual net income on record is $263M, achieved in fiscal year 2018. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were INDV's earnings last quarter?
INDV's most recent reported quarter was Q1 2026. Net income was $89M with diluted EPS of $0.69. For a full breakdown of all quarters, see the quarterly earnings table on this page.